文献速递前列腺癌

晚期前列腺癌中雄激素受体改变的临床意义:一项多机构协作研究

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-02-22

本研究基于PROMISE数据库,纳入540例接受ARTA治疗且完成基因组检测的CRPC患者,按检测时机分为ARTA前与ARTA后两组。ARTA前检测者中AR扩增患者至进展时间25.7个月,长于无AR改变者的9.6个月(p=0.03)。作者认为AR扩增与首次ARTA治疗至进展时间更长相关,需进一步前瞻性研究。

要点

  • 540例CRPC患者接受ARTA治疗并完成组织或血液基因组检测。
  • ARTA前检测者中,AR扩增患者至进展时间25.7个月,无AR改变者9.6个月(p=0.03)。
  • ARTA后检测者中AR突变18.5%、AR扩增35.7%,最常见突变为L702H(9.9%)。

核心结论

  • 在真实世界临床基因组数据库中,AR扩增与首次ARTA治疗至进展时间更长相关。
  • 作者认为需进一步前瞻性研究以优化AR改变患者的治疗策略。

研究设计与样本

  • 研究为真实世界临床基因组数据库驱动的多机构协作研究,数据来自PROMISE数据库。
  • 纳入540例接受ARTA治疗且完成基因组检测的CRPC患者,组织检测321例、血液检测244例。
  • 按基因组检测相对于首次ARTA治疗的时机分为ARTA前和ARTA后两组。
  • 诊断时中位年龄62岁(范围39-90),多数为白人(72.2%),首次ARTA治疗时92.6%有转移性疾病。

主要发现

  • ARTA前基因组检测可用者占24.8%,AR突变和AR扩增分别见于8.2%和13.1%的患者。
  • AR扩增患者至进展时间25.7个月,无AR改变患者9.6个月(p=0.03)。
  • ARTA后组(n=406)中AR突变和AR扩增分别见于18.5%和35.7%的患者。
  • ARTA后组最常见突变为L702H(9.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步前瞻性研究以优化AR改变患者的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes remains unclear. METHODS: Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing and received ARTA treatment were identified in the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. Patients were stratified according to the timing of genomic testing relative to the first ARTA treatment (pre-/post-ARTA). Clinical outcomes such as time to progression, PSA response, and overall survival were compared based on alteration types. RESULTS: In total, 540 CRPC patients who received ARTA and had tissue-based (n = 321) and/or blood-based (n = 244) genomic sequencing were identified. Median age was 62 years (range 39-90) at the time of the diagnosis. Majority were White (72.2%) and had metastatic disease (92.6%) at the time of the first ARTA treatment. Pre-ARTA genomic testing was available in 24.8% of the patients, and AR mutations and amplifications were observed in 8.2% and 13.1% of the patients, respectively. Further, time to progression was longer in patients with AR amplifications (25.7 months) compared to those without an AR alteration (9.6 months; p = 0.03). In the post-ARTA group (n = 406), AR mutations and AR amplifications were observed in 18.5% and 35.7% of the patients, respectively. The most common mutation in post-ARTA group was L702H (9.9%). CONCLUSION: In this real-world clinicogenomics database-driven study we explored the development of AR alterations and their association with ARTA treatment outcomes. Our study showed that AR amplifications are associated with longer time to progression on first ARTA treatment. Further prospective studies are needed to optimize therapeutic strategies for patients with AR alterations.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Zengin ZB, Henderson NC, Park JJ, et al. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer Prostatic Dis. 2024. PMID: 38383885. doi:10.1038/s41391-024-00805-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。